HOME >> BIOLOGY >> NEWS
St. Jude study shows genes play an unexpected role in their own activation

Investigators at St. Jude Children's Research Hospital have discovered how a single molecular on switch triggers gene activity that might cause effects ranging from learning and memory capabilities to glucose production in the liver.

The on switch, a protein called CREB, is a transcription factora molecule that binds to a section of DNA near a gene and triggers that gene to make the specific protein for which it codes. CREB activates genes in response to a molecule called cAMP, which acts as a messenger for a variety of stimuli including hormones and nerve-signaling molecules called neurotransmitters.

The St. Jude team showed that each gene that responds to CREB chooses which co-factors, or helper molecules, CREB uses to activate that gene. This finding adds an important piece to the puzzle of how cells use CREB to activate specific genes in response to cAMP signals.

It also suggests that the current model scientists use to explain how CREB works is too simple, said Paul Brindle, Ph.D., associate member of the Department of Biochemistry at St. Jude. Brindle is senior author of a report on this work that appears in the June 20 issue of The EMBO Journal.

CREB is like a plumber who turns on the water flow in a pipe system by using a certain tool, Brindle said. What we discovered is that the CREB plumber requires different tools to turn on different genes; and that each gene determines which set of co-factor tools from CREBs toolbox it will respond to.

In order to activate a gene, CREB must first get tagged by a molecule called phosphate. CREB then recruits a co-factor called CBP/p300 to the gene by binding to this protein at a site called KIX. Previously, scientists thought that a particular transcription factor uses the same co-factors to activate all its target genes.

The new findings showed that phosphate-tagged CREB binding to CBP/p300 at KIX does not account for most gene activation controlled by
'"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
22-Jun-2007


Page: 1 2

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... B.V. (MBS) has announced a publication detailing the use of its revolutionary ... polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... date growth of 40% in 2020, despite many obstacles created as a result ... to increase revenue for its partnered medical practices and medical manufacturers by expanding ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association ... of DRP-104; and, the other profiles the potent, consistent single agent activity in ...
Breaking Biology Technology:
Cached News: